

CLINICAL TRIAL FOR PEOPLE WITH PARKINSON'S DISEASE FOR LESS THAN 2 YEARS

What is this study about?

This research study is testing a new medication called BHV-8000 for Parkinson's disease. Scientists believe that inflammation (swelling) in the brain plays a major role in Parkinson's. BHV-8000 works by reducing this inflammation, which may help slow down the progression of the disease.

Who can participate?

You may qualify if you:

- Are between 40 and 85 years old
- Have been diagnosed with Parkinson's disease within the past 2 years
- Are not currently taking Parkinson's medications and are a non-smoker (including e-cigarettes)

You likely won't qualify if you:

- Have other types of Parkinsonism (like multiple system atrophy or drug-induced Parkinsonism)
- Have other significant brain conditions besides Parkinson's

How long does it take?

Total time: About 14 months (60 weeks)

- **Screening:** Up to 8 weeks (may require multiple visits for tests)
- **Main Study:** 48 weeks with 10 visits total
- **Follow-up:** 1 final visit, 4 weeks after the main study ends

Where is it located?

New Haven, Connecticut

What happens during the study?

Participants will receive either BHV-8000 or a placebo (some participants will get the real medication, others will get an inactive version). Throughout the study, participants will have regular check-ins to monitor their Parkinson's symptoms and overall health.

Why participate?

- Help advance research that may slow Parkinson's progression
- Receive close medical monitoring throughout the study
- Contribute to potential new treatment options for the Parkinson's community

Questions?

XING/INDD Research Team

Phone: (475) 318-8250 (*24/7 messaging available)

Address: 55 Church Street, 7th Floor, New Haven, CT 06510

Websites: <https://xingimaging.com/> | www.indd.org